Anti-ANKRD11 monoclonal antibody
Pre-made anti-ANKRD11 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to ANKRD11/ANKRD11 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP2343-Ab-1/ GM-Tg-hg-IP2343-Ab-2 | Anti-Human ANKRD11 monoclonal antibody | Human |
GM-Tg-rg-IP2343-Ab-1/ GM-Tg-rg-IP2343-Ab-2 | Anti-Rat ANKRD11 monoclonal antibody | Rat |
GM-Tg-mg-IP2343-Ab-1/ GM-Tg-mg-IP2343-Ab-2 | Anti-Mouse ANKRD11 monoclonal antibody | Mouse |
GM-Tg-cynog-IP2343-Ab-1/ GM-Tg-cynog-IP2343-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ANKRD11 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP2343-Ab-1/ GM-Tg-felg-IP2343-Ab-2 | Anti-Feline ANKRD11 monoclonal antibody | Feline |
GM-Tg-cang-IP2343-Ab-1/ GM-Tg-cang-IP2343-Ab-2 | Anti-Canine ANKRD11 monoclonal antibody | Canine |
GM-Tg-bovg-IP2343-Ab-1/ GM-Tg-bovg-IP2343-Ab-2 | Anti-Bovine ANKRD11 monoclonal antibody | Bovine |
GM-Tg-equg-IP2343-Ab-1/ GM-Tg-equg-IP2343-Ab-2 | Anti-Equine ANKRD11 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP2343-Ab-1/ GM-Tg-hg-IP2343-Ab-2; GM-Tg-rg-IP2343-Ab-1/ GM-Tg-rg-IP2343-Ab-2; GM-Tg-mg-IP2343-Ab-1/ GM-Tg-mg-IP2343-Ab-2; GM-Tg-cynog-IP2343-Ab-1/ GM-Tg-cynog-IP2343-Ab-2; GM-Tg-felg-IP2343-Ab-1/ GM-Tg-felg-IP2343-Ab-2; GM-Tg-cang-IP2343-Ab-1/ GM-Tg-cang-IP2343-Ab-2; GM-Tg-bovg-IP2343-Ab-1/ GM-Tg-bovg-IP2343-Ab-2; GM-Tg-equg-IP2343-Ab-1/ GM-Tg-equg-IP2343-Ab-2 |
Products Name | Anti-ANKRD11 monoclonal antibody |
Format | mab |
Target Name | ANKRD11 |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-ANKRD11 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP2343-Ag-1 | Recombinant multi-species ANR11/ ANKRD11/ ANCO-1 protein |
Target information
Target ID | GM-IP2343 |
Target Name | ANKRD11 |
Gene ID | 29123,77087,365023,698722,489658,101100431,532856,100050107 |
Gene Symbol and Synonyms | 2410104C19Rik,3010027A04Rik,6330578C09Rik,9530048I21Rik,ANCO-1,ANCO1,ANKRD11,Gm176,LZ16,T13,Yod |
Uniprot Accession | Q6UB99 |
Uniprot Entry Name | ANR11_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000167522 |
Target Classification | N/A |
The target: ANKRD11, gene name: ANKRD11, also named as ANCO-1, ANCO1, LZ16, T13. This locus encodes an ankryin repeat domain-containing protein. The encoded protein inhibits ligand-dependent activation of transcription. Mutations in this gene have been associated with KBG syndrome, which is characterized by macrodontia, distinctive craniofacial features, short stature, skeletal anomalies, global developmental delay, seizures and intellectual disability. Alternatively spliced transcript variants have been described. Related pseudogenes exist on chromosomes 2 and X. [provided by RefSeq, Jan 2012].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.